1068GCC Evaluate Efficacy & Explore Mechanism of Acupuncture in Treating Bortezomib-induced Peripheral Neuropathy (BIPN) in Multiple Myeloma
NCT01541644 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 27
Last updated 2019-11-07
Summary
Patients are asked to be in this study if they have multiple myeloma and are having tingling, numbness and pain from taking bortezomib (velcade®). Patients who have been diagnosed with multiple myeloma often take bortezomib (velcade®).
This research is being done to find out if acupuncture can reduce the nerve pain, tingling, and/or numbness patients experience due to bortezomib (velcade®).
Acupuncture is a medical technique of inserting very thin needles into the "energy points" on the body with the aim to restore health and well-being. It has been used widely to treat pain, such as lower back pain and nerve pain. In this study we will see if acupuncture can be used to ease nerve pain and tingling, numbness that is caused by bortezomib.
Conditions
- Peripheral Neuropathies
- Multiple Myeloma
Interventions
- DEVICE
-
Acupuncture
Participants will receive acupuncture treatment twice weekly for 2 weeks, then once per week for 4 weeks, and then biweekly for 4 weeks.
Sponsors & Collaborators
-
University of Maryland, Baltimore
lead OTHER
Principal Investigators
-
Ting Bao, MD, DABMA · University of Maryland Marlene & Stewart Greenebaum Cancer Center
Study Design
- Allocation
- NA
- Purpose
- SUPPORTIVE_CARE
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2011-05-31
- Primary Completion
- 2012-06-30
- Completion
- 2014-12-31
Countries
- United States
Study Locations
More Related Trials
-
Bortezomib (Velcade) Post Allogenic Peripheral Blood Stem Cell Transplantation for Myeloma
NCT00504634 ·Status: COMPLETED ·Phase: PHASE2
-
An Observational Study of Chinese Multiple Myeloma Patients Treated With Velcade
NCT01675245 ·Status: COMPLETED
-
Study of Risk Factors and Genetic Association With Bortezomib-induced Peripheral Neuropathy in Multiple Myeloma
NCT03210753 ·Status: UNKNOWN
-
An Efficacy and Safety Study of Bortezomib Re-treatment in Multiple Myeloma
NCT00431769 ·Status: COMPLETED ·Phase: PHASE2
-
Perspectives of Subcutaneous Velcade at Home of Patients With Myeloma.
NCT05163405 ·Status: COMPLETED
-
Expanded Access Protocol (EAP) to Provide Bortezomib to Patients With Multiple Myeloma Who Have Received at Least 2 Previous Lines of Therapy and Are Refractory to or Have Relapsed After Their Last Therapy for Multiple Myeloma
NCT00440635 ·Status: COMPLETED
-
Effects of Bortezomib-Based Therapy on Cellular Immunity and Response to DC/Myeloma Fusion Vaccines in Vitro
NCT01472627 ·Status: COMPLETED
-
Bortezomib, Doxorubicin Hydrochloride Liposome, and Thalidomide as First-line Therapy in Treating Patients With Previously Untreated Stage I, II, or III Multiple Myeloma
NCT00523848 ·Status: COMPLETED ·Phase: PHASE2
-
Study of Subcutaneous Versus Intravenous Administration of Bortezomib in Patients With Multiple Myeloma in China
NCT01812096 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2
-
Efficacy of Monosialotetrahexosylganglioside in the Prophylactic Treatment of Bortezomib-induced Peripheral Neuropathy
NCT02093910 ·Status: UNKNOWN ·Phase: PHASE2
-
Safety and Efficacy Study of Single Weekly Bortezomib in Newly Diagnosed Multiple Myeloma
NCT01090921 ·Status: COMPLETED ·Phase: PHASE2
-
Repeat-Dose Pharmacokinetics and Pharmacodynamics of Bortezomib in Patients With Relapsed Multiple Myeloma
NCT00080405 ·Status: COMPLETED ·Phase: PHASE1
-
The Efficacy of Velcade on Bone Tissue During Myelomatosis (Bone Marrow Cancer)
NCT00436059 ·Status: COMPLETED ·Phase: PHASE2
-
A Study of ATN-224 and Bortezomib in Patients With Multiple Myeloma
NCT00352742 ·Status: TERMINATED ·Phase: PHASE1/PHASE2
-
Study of Subcutaneous and Intravenous Velcade in Combination With Dexamethasone in Chinese Subjects With Relapsed and Refractory Multiple Myeloma
NCT02811978 ·Status: COMPLETED ·Phase: PHASE3
-
Doxorubicin Hydrochloride Liposome, Melphalan, and Bortezomib in Treating Patients With Relapsed or Refractory Stage I, Stage II, or Stage III Multiple Myeloma
NCT00334932 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2
-
CyBorD vs. PAD in the Treatment of Newly Diagnosed Multiple Myeloma
NCT02362165 ·Status: UNKNOWN ·Phase: PHASE3
-
Consolidation Therapy With Bortezomib in Elderly Patients With Multiple Myeloma
NCT00416208 ·Status: COMPLETED ·Phase: PHASE3
-
Protocol of the Combination of Bortezomib and Tipifarnib for Relapsed or Refractory Multiple Myeloma
NCT00972712 ·Status: COMPLETED ·Phase: PHASE1
-
Weekly Bortezomib (Velcade) in the Treatment of Patients With Refractory Multiple Myeloma
NCT00193557 ·Status: COMPLETED ·Phase: PHASE2
-
Preemptive Strike With Bortezomib in Multiple Myeloma Patients
NCT00657553 ·Status: TERMINATED ·Phase: PHASE3
-
Evaluation of VELCADE Given as Retreatment to Multiple Myeloma Patients for Efficacy, Safety and Tolerability
NCT00257114 ·Status: COMPLETED ·Phase: PHASE4
-
Autophagy Induction After Bortezomib for Myeloma
NCT01594242 ·Status: COMPLETED ·Phase: EARLY_PHASE1
-
Combination CCI-779 (Temsirolimus) and Bortezomib (Velcade) in Relapsed and/or Relapsed/Refractory Multiple Myeloma
NCT00483262 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Evaluation of Cardiotoxic Effects of Bortezomib
NCT02026505 ·Status: COMPLETED